Mergers & Acquisitions
Filter News
Found 21,477 articles
-
2024 Predictions for Biotech M&As
1/3/2024
Continued fallout from the IRA, heightened antitrust enforcement and the rise of AI will all shape the first wave of biotech mergers and acquisitions coming this year, experts tell BioSpace. -
Tome Biosciences has only been on the scene for a short time but on Tuesday notched an acquisition of CRISPR-based biotech Replace Therapeutics for $65 million upfront. -
Bruker Acquires Electron Microscopy Company Nion
1/3/2024
Bruker announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes.
-
Enovis Completes Acquisition of LimaCorporate S.p.A
1/3/2024
Enovis™ Corporation an innovation-driven, medical technology growth company, announced that it closed the acquisition of LimaCorporate S.p.A., a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.
-
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
1/3/2024
Cosette Pharmaceuticals Acquires Vyleesi ® (Bremelanotide Injection) from Palatin Technologies Inc.
-
Align Technology Completes Acquisition of Cubicure, a Pioneer of Direct 3D Printing Solutions for Polymer Additive Manufacturing
1/3/2024
Align Technology, Inc. announced that it has completed the acquisition of privately-held Cubicure GmbH, a pioneer in direct 3D printing solutions for polymer additive manufacturing that develops, produces, and distributes innovative materials, equipment, and processes for novel 3D printing solutions.
-
Hera Biotech to Make First Acquisition in the Endometriosis Diagnostic Market and Enter Into Strategic Partnership With Scailyte
1/3/2024
Hera Biotech announced today that it has reached an agreement to acquire the endometriosis diagnostic assets and associated IP of single-cell and AI-driven biomarker discovery company Scailyte, creating an important consolidation of the only two tissue-based diagnostic programs for endometriosis.
-
All three companies closed out the year, which saw significant growth in mergers and acquisitions, with high-value deals that could potentially set the tone for M&A in 2024.
-
Tome Biosciences Acquires Replace Therapeutics
1/2/2024
Tome Biosciences, Inc., the programmable genomic integration company, announces that it has acquired Replace Therapeutics Inc., a private biotechnology company developing a novel PGI method capable of inserting and deleting small DNA sequences.
-
Frontage Laboratories Acquires Accelera S.r.l.'s Bioanalytical and DMPK Businesses
1/2/2024
Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).
-
Novanta completes acquisition of Motion Solutions
1/2/2024
Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has completed the acquisition of Motion Solutions.
-
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
1/2/2024
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.’s (OTCQB: ODYY) (“Odyssey”) proprietary neurological drug therapies and technologies.
-
Calibre Scientific Acquires LineaLAB
1/2/2024
Calibre Scientific has acquired LineaLAB, SL, a provider of analytical, bio and laboratory equipment based in Badalona.
-
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
1/2/2024
PharmaGend Global Medical Services Pte. Ltd., jointly invested by China Medical System Holdings Limited, through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron International Limited and Healthy Goal Limited, has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte.
-
Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools
12/28/2023
Dr. Larry Gold, the founder of SomaLogic, Inc. and Dr. Jason Cleveland, SomaLogic's current Chief Technology Officer, are issuing the below letter to SomaLogic's stockholders regarding their opposition to the Company's proposed merger with Standard BioTools, Inc. .
-
Enpro Inc. to Acquire Advanced Micro Instruments, Inc.
12/28/2023
Enpro Inc. announced that it has entered into a definitive agreement to acquire Advanced Micro Instruments, Inc., a leading provider of highly-engineered, application-specific analyzers and sensing technologies that monitor critical parameters to maintain infrastructure integrity, enable process efficiency, enhance safety, and facilitate the clean energy transition.
-
Lilly Completes Acquisition of POINT Biopharma
12/27/2023
Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
-
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
12/27/2023
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. announced the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction.
-
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
12/27/2023
Visiox Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market.
-
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
12/27/2023
Cosmos Health Inc. provided a business update highlighting the expected revenue growth resulting from the various companies and assets it acquired within 2023, as well as a forecast for revenue, gross profit, and EBITDA in the upcoming year, exclusively attributed to these acquisitions.